[go: up one dir, main page]

MX2012010691A - Composiciones farmaceuticas de ligandos receptores de secretagoga de la hormona de crecimiento. - Google Patents

Composiciones farmaceuticas de ligandos receptores de secretagoga de la hormona de crecimiento.

Info

Publication number
MX2012010691A
MX2012010691A MX2012010691A MX2012010691A MX2012010691A MX 2012010691 A MX2012010691 A MX 2012010691A MX 2012010691 A MX2012010691 A MX 2012010691A MX 2012010691 A MX2012010691 A MX 2012010691A MX 2012010691 A MX2012010691 A MX 2012010691A
Authority
MX
Mexico
Prior art keywords
present
compositions
pharmaceutical compositions
growth hormone
receptor ligands
Prior art date
Application number
MX2012010691A
Other languages
English (en)
Other versions
MX343499B (es
Inventor
Zheng Xin Dong
Jundong Zhang
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of MX2012010691A publication Critical patent/MX2012010691A/es
Publication of MX343499B publication Critical patent/MX343499B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con mejoras en las composiciones que contienen péptidos que son ligandos del receptor de GHS, o sus sales farmacéuticamente aceptables, métodos para la preparación de dichas composiciones, y métodos para el uso de dichas composiciones para tratar mamíferos. En particular, la presente invención se relaciona con una composición farmacéutica que comprende una sal de pamoato de H-Inp-D-Bal-D-Trp-Phe-Apc-NH 2, que es un ligando del receptor de GHS y en la cual, después de su administración subcutánea o intramuscular a un sujeto, el péptido forma un depósito insítu a un pH fisiológico que es lentamente disuelto y liberado en el fluido corporal y en el torrente sanguíneo. La presente invención puede comprender, además, un componente orgánico tal como dimetilacetamida (DMA) o polietilenglicol con un peso molecular promedio menor a 1000.
MX2012010691A 2010-03-15 2011-03-14 Composiciones farmaceuticas de ligandos receptores de secretagoga de la hormona de crecimiento. MX343499B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34029010P 2010-03-15 2010-03-15
PCT/US2011/028283 WO2011115871A1 (en) 2010-03-15 2011-03-14 Pharmaceutical compositions of growth hormone secretagogue receptor ligands

Publications (2)

Publication Number Publication Date
MX2012010691A true MX2012010691A (es) 2013-01-25
MX343499B MX343499B (es) 2016-11-08

Family

ID=44649531

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010691A MX343499B (es) 2010-03-15 2011-03-14 Composiciones farmaceuticas de ligandos receptores de secretagoga de la hormona de crecimiento.

Country Status (14)

Country Link
US (2) US20130210751A1 (es)
EP (1) EP2547351B1 (es)
JP (2) JP5977225B2 (es)
KR (1) KR101589191B1 (es)
CN (1) CN102821775B (es)
AU (1) AU2011227532B2 (es)
BR (1) BR112012023303A2 (es)
CA (1) CA2792866C (es)
ES (1) ES2579941T3 (es)
HK (1) HK1180599A1 (es)
MX (1) MX343499B (es)
RU (1) RU2523566C2 (es)
UA (1) UA104945C2 (es)
WO (1) WO2011115871A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932231B2 (en) 2005-09-29 2011-04-26 Ipsen Pharma, S.A.S. Compositions and methods for stimulating gastrointestinal motility
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
MX337286B (es) 2007-05-25 2016-02-22 Indivior Uk Ltd Formulaciones de transferencia sostenida de compuestos de risperidona.
JP5486690B2 (ja) 2009-11-16 2014-05-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンドの医薬組成物
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB201012980D0 (en) * 2010-08-03 2010-09-15 Johnson Matthey Plc Membrane
TWI523863B (zh) 2012-11-01 2016-03-01 艾普森藥品公司 體抑素－多巴胺嵌合體類似物
RU2015120570A (ru) 2012-11-01 2016-12-20 Ипсен Фарма С.А.С. Аналоги соматостатина и их димеры
WO2015134567A1 (en) * 2014-03-04 2015-09-11 Rhythm Pharmaceuticals, Inc. Process for the liquid phase synthesis of h-inp-(d)bal-(d)trp-phe-apc-nh2, and pharmaceutically acceptable salts thereof
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CN113045625B (zh) * 2021-03-30 2023-11-07 成都诺和晟泰生物科技有限公司 作为生长激素促分泌素受体激动剂的多肽及其应用
CN113072617B (zh) * 2021-03-30 2023-08-08 成都诺和晟泰生物科技有限公司 一种多肽化合物及其应用
CN114805487B (zh) * 2022-06-07 2024-03-12 成都诺和晟泰生物科技有限公司 一种多肽化合物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE267613T1 (de) * 1998-03-05 2004-06-15 Phares Pharm Res Nv Arzneimittel und deren verwendung
US20010020012A1 (en) * 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
CA2420535A1 (en) * 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
US7521527B2 (en) * 2003-12-16 2009-04-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. GLP-1 pharmaceutical compositions
CA2603295A1 (en) * 2004-04-07 2006-10-20 Gastrotech Pharma A/S Use of ghrelin for the treatment of hyperthyroidism
GB0412866D0 (en) * 2004-06-09 2004-07-14 Novartis Ag Organic compounds
US7932231B2 (en) * 2005-09-29 2011-04-26 Ipsen Pharma, S.A.S. Compositions and methods for stimulating gastrointestinal motility
KR20150017777A (ko) * 2006-01-18 2015-02-17 포시에이서 파마슈티컬스 인코포레이티드 안정성이 강화된 약학 조성물
EP2012809B1 (en) * 2006-03-10 2013-05-22 Ipsen Pharma Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment
CA2665101A1 (en) * 2006-10-05 2008-04-10 Panacea Biotec Ltd. Injectable depot composition and it's process of preparation
TW200916113A (en) * 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
CN102088998A (zh) * 2008-05-14 2011-06-08 益普生制药股份有限公司 生长激素释放抑制因子-多巴胺缀合物的药物组合物
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
JP5951991B2 (ja) * 2008-08-12 2016-07-13 ノバルティス アーゲー 医薬組成物
IE20100174A1 (en) * 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides

Also Published As

Publication number Publication date
AU2011227532B2 (en) 2014-03-13
US20160220637A1 (en) 2016-08-04
UA104945C2 (uk) 2014-03-25
JP2013522301A (ja) 2013-06-13
CA2792866C (en) 2016-05-31
ES2579941T3 (es) 2016-08-17
EP2547351B1 (en) 2016-04-27
CN102821775A (zh) 2012-12-12
AU2011227532A1 (en) 2012-09-13
JP5977225B2 (ja) 2016-08-24
RU2523566C2 (ru) 2014-07-20
US20130210751A1 (en) 2013-08-15
JP2015163620A (ja) 2015-09-10
CN102821775B (zh) 2014-10-22
BR112012023303A2 (pt) 2020-08-25
CA2792866A1 (en) 2011-09-22
WO2011115871A1 (en) 2011-09-22
HK1180599A1 (zh) 2013-10-25
KR101589191B1 (ko) 2016-01-27
RU2012143747A (ru) 2014-04-20
EP2547351A4 (en) 2013-08-28
KR20130004334A (ko) 2013-01-09
EP2547351A1 (en) 2013-01-23
MX343499B (es) 2016-11-08

Similar Documents

Publication Publication Date Title
MX2012010691A (es) Composiciones farmaceuticas de ligandos receptores de secretagoga de la hormona de crecimiento.
US20220160818A1 (en) Pharmaceutical compositions
ZA202202410B (en) Rna particles comprising polysarcosine
WO2011054001A3 (en) Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
CA2660208A1 (en) Cyclic angiotensin analogs
WO2012054500A3 (en) Compositions for drug administration
TW201536346A (zh) 用於持續釋放蘭瑞肽之醫藥組成物
WO2009139855A3 (en) Pharmaceutical compositions of somatostatin-dopamine conjugates
ES2515097T3 (es) Formulación de liberación sostenida que comprende un análogo de somatostatina
RU2015119472A (ru) Терапевтическое средство для бокового амиотрофического склероза
US20170035884A1 (en) Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
US20170035855A1 (en) Medicinal agent for suppressing malignant tumor metastasis
RU2018132694A (ru) Фармацевтическая композиция, включающая рекомбинантный гормон роста человека для лечения дефицита гормона роста
CN1780635B (zh) 肝病的预防或治疗剂
RU2017132449A (ru) Фармацевтические композиции ингибитора c1-эстеразы
JP7357292B2 (ja) 癌治療用ペプチド
WO2019185881A1 (en) Compositions

Legal Events

Date Code Title Description
FG Grant or registration